1.. Introduction
================

Renal-cell carcinoma (RCC) is the most common kidney neoplasm, comprising 3% of all adult malignancies ([@b22-cin-03-65]). Its incidence has increased steadily over the past 20 years in the United States and Europe; 35,000 new cases and 12,000 deaths now occur annually in the United States alone. Histopathologically, about 60--70% of RCC is clear-cell type (cc-RCC). Small and localized tumors are generally asymptomatic; pain, flank mass, or hematuria, being generally associated with locally advanced or metastatic tumors. Diagnosis is confirmed by imaging, including X-ray and computed-tomography. The 5-year survival rate of metastatic RCC is less than 10%. Moreover, RCC is one of the most therapy-resistant carcinomas, responding very poorly or not at all to radiotherapy, hormonal therapy, and chemotherapy. All these facts emphasize the importance of developing early diagnostic markers.

Microarray gene expression profiling has been used by ourselves ([@b27-cin-03-65]) and others ([@b51-cin-03-65]; [@b3-cin-03-65]; [@b9-cin-03-65]; [@b52-cin-03-65]; [@b50-cin-03-65]; [@b27-cin-03-65]; [@b14-cin-03-65]; [@b43-cin-03-65]; [@b41-cin-03-65]; [@b23-cin-03-65]) to distinguish the various histological subtypes of RCC, and consequently to identify novel tumor markers. The general procedure identifies markers in accordance with average differential expression level (fold change) and/or some level of significance as measured by the t-test. Lenburg et al. used a 3-fold difference in expression and a level of significance of 0.03.

Here, we reanalyze the data of Lenburg et al. using a rigorous exhaustive search approach ([@b6-cin-03-65]), and a more general, but approximate, approach based on support vector machines. We identify, by exhaustive search, 158 genes each of which (i) is consistently over- or under-expressed in all tumors and (ii) has a minimum expression level difference at better than 99% confidence. Sixty four of these *markers* were not identified previously ([@b27-cin-03-65]). The set is highly enriched in cancer related genes (p = 1.6 × 10^−12^), containing 43 previously associated with either RCC or other types of cancer.

Among the set of genes that we identify as being related to RCC, some were known from previous studies (e.g. ATP6V1B1, EGLN3, SLC25A5, TUBB, ALDOA); others had never before been associated with RCC, but have been identified with other cancers (e.g. ABL2, JAZF1, TFAP2A). We identified biological roles of marker genes, and found pathways that are dominantly up-regulated (83% of immune response genes, all amino acid transport genes) or down-regulated (all cation and anion transport genes, all OXPHOS genes) which are related to kidney function (cation/anion transport genes) and RCC physiology (OXPHOS). Finally we constructed a model for RCC through functional classification of genes related to changes in cellular processes that are critical to initiation and progression of cancer.

2.. Methods
===========

2.0.. Background
----------------

Briefly, ([@b27-cin-03-65]) hybridized total RNA isolated from 9 clear-cell renal tumors and adjacent normal tissue (18 samples) to Affymetrix U133A and U133B arrays containing approximately 45,000 probe-sets. Of these, 27,609, representing 20,192 unigenes, gave a signal above background. Differentially expressed genes were identified by t-test and fold change. The average fold change was calculated as log~2~ (C/N) where C and N represent the average of tumor and normal expression values, respectively. Some 1706 probe-sets (1471 unique genes) were more than three-fold changed in renal tumors and had a p-value \<0.03. Of these, 113 had been previously identified in three or more studies ([@b51-cin-03-65]; [@b3-cin-03-65]; [@b42-cin-03-65]; [@b9-cin-03-65]). An obvious limitation of drawing conclusions from such a study is the small number of samples per category with a relatively large number of potential markers. We discuss this in detail below.

2.1.. Identifying single gene biomarkers by exhaustive search
-------------------------------------------------------------

Here we identify single genes that correctly classify every sample, by direct comparison of differential expression in every tumor-normal pair (9^2^ comparisons per gene × 20,192 genes). A gene whose level of expression in every normal sample is always either greater or less than its level in every tumor sample, is ranked according to the smallest expression level distance across the two categories (Perl script is available at <http://visant.bu.edu/skirca/script.pl>). The smallest separation for a down (up)-regulated gene is the difference between the maximum (minimum) expression level in the tumor samples, and the minimum (maximum) expression level in the normal samples. In particular define *E~m,i~* as the expression level of the i^th^ gene in the m^th^ tumor sample and let *E~n,i~* be similarly defined for the normal samples. The minimum distance for the i^th^ gene is defined as $$d_{i} = \text{min}{|\left\{ E_{m,i} - E_{n,i} \right\}|}$$provided all differences have the same sign, where m and n range independently over all samples.

We identified 478 probes, corresponding to 466 unique genes, that separate all tumor from all normal tissue. Each gene was then tested for significance as follows.

For a given gene we randomly selected 9 tumor expression values from all tumor expression values (20,192 genes × 9 tumor samples = 181,728 expression values), and 9 normal values from all normal expression values, subject to the constraint that all tumor values are greater (less) than all normal values. We calculated the minimum distance and repeated the procedure 500 times (to mimic random selection of 466 genes) to obtain a distribution of minimum distances ([Figure 1(a)](#f1-cin-03-65){ref-type="fig"}). The procedure was repeated 200 times to estimate the dispersion in the parameters of the sampling distribution. Overall, we obtained skew minimum distance distributions with an average mean minimum distance 0.0425 (standard deviation over 200 simulations = 0.00261) and average standard deviation 0.05768 (standard deviation over 200 simulations = 0.00531) across all simulations. The p-value for each actual minimum distance (d) was calculated using the total random data (500 × 200 = 10^5^) as probability of finding ≥d randomly (P(d~random~ ≥d). Of the initial set of 466 genes 158 were found to have significant minimum distances \>0.28 with p-value ≤0.01 ([Figure 1(b)](#f1-cin-03-65){ref-type="fig"}). We refer to these as *significant single gene biomarkers* or simply *markers*.

2.2.. SVM Recursive feature elimination
---------------------------------------

An alternative strategy for selecting markers is to use statistical feature selection techniques to rank genes. This can be done in a number of ways. Here we use a support vector machine (SVM) ([@b45-cin-03-65]). which has been used effectively in other contexts ([@b15-cin-03-65]; [@b16-cin-03-65]; [@b17-cin-03-65]), and which has a well established statistical framework. The idea is again to find genes whose distance between tumor/normal sample expression values is in some sense maximum. Guyon et al. ([@b11-cin-03-65]) used a similar method to identify genes that stratify leukemia ([@b10-cin-03-65]), and for distinguishing between colon cancer and normal tissue ([@b2-cin-03-65]), by dividing the data sets into two equal halves for training and testing. They recursively discarded the features (genes) with smallest weight (see below for detailed discussion) to select genes that separate the two classes at a specified accuracy. For leukemia they discovered 2 genes that yield zero leave-one-out error. For colon cancer, they obtained 98% accuracy using 4 genes. The main difference here is the introduction of a procedure that does not assume the highest ranked gene is necessarily more useful than genes that rank slightly lower.

An SVM is an effective method for making predictions on many types of data including handwritten text, protein sequence, DNA sequence, and microarray profiles, when the number of data attributes for each sample is very large. Briefly, the method seeks to find a maximal separation between two training sets ([@b39-cin-03-65]), a positive set, in this case tumor samples; and a negative set, normal samples. Each sample is labeled by a set of attributes, here gene expression levels, and hence can be represented by a vector that can have tens of thousands of components. The separation between positive and negative vectors (samples) is achieved through an optimization which finds a hyperplane bisecting the two sets. The hyperplane must be as distant as possible from the two sets thus creating a *maximal-margin* separator ([@b15-cin-03-65]).

Most of the attributes are irrelevant to separation. The SVM algorithm can be used to rank the importance of the various attributes by a method referred to as recursive feature elimination (RFE), and thus identify those genes that are most discriminatory. An important SVM output is a vector of learned weights; each component of the vector being a weight of an attribute: the higher the weight the more useful in separating positives from negatives. The original SVM-RFE algorithm trains an SVM, calculates the weight of each attribute, and discards a specified number of low weight attributes ([@b11-cin-03-65]). The process is repeated until the desired number of attributes remains. Typically half the attributes are removed at each iteration until some threshold is reached after which only one at a time is removed.

The procedure employed here is different in that the entire SVM-RFE ranking is performed many times within a leave-one-out cross validation. Briefly, the procedure is as follows. Prior to applying the SVM, we use a t-test with a loose p-value threshold of 0.1 to filter the large majority of statistically irrelevant genes, leaving 10,479 genes for further analysis. We then perform SVM-RFE on *n*-1 samples, save the results, and repeat *n* times. Thus for the renal cancer dataset with n = 18 samples we ranked the performance of each gene 18 times (18 cross-validations). Intuitively, genes that are repeatedly ranked near the top are robust to changes in the training set and are considered more reliable. The fluctuation of gene choice during cross validation can be seen more clearly when examining a list showing the highest ranked gene on each training set of the leave-one-out procedure. On the 18 possible training sets, 12 different genes were given a rank of 1 at least once (data not shown). Because gene rank can change markedly with dataset, choosing consistent genes increases the chances that the chosen genes are truly reliable markers. *This highlights the need to choose genes that are consistent across samples, as opposed to genes whose average value differs significantly across the two categories.*

To derive our final gene ranking, we arbitrarily selected the top 20 genes from each ranking and counted the number of times each gene appears in this combined set. The maximum occurrence of 18 would indicate a very stable biomarker; i.e. one that was chosen by each training set. The final list represents genes that are stable across sample sets and can thus be considered reliable biomarkers.

3.. Results
===========

3.1.. Single gene markers
-------------------------

### Pathway/process enrichment

Of the 158 markers, 73 are annotated in a KEGG pathway and another 42 are in a GO process at level 5 or higher. The pathways/processes with the highest number of classifiers are shown in [Table 1](#t1-cin-03-65){ref-type="table"}. The categories are biologically plausible, having already been implicated in cancer transformation (e.g. OXPHOS, apoptosis, cell adhesion, MAPK signaling) or being potentially important (calcium signaling pathway, fatty acid metabolism and cation transport) in transformation.

### Marker Significance

We ([@b27-cin-03-65]) previously identified 1471 genes that were more than three-fold changed in renal tumors with a p-value \<0.03. The relationship between minimum distance determined by exhaustive search, and the average fold change, is shown in [Figure 2](#f2-cin-03-65){ref-type="fig"}. Of the 158 *markers* (indicated in red) 94 (59%) have changed at least 3 fold in tumor with a t-test p-value \<0.03, and hence overlap with the 1471 genes identified by ([@b27-cin-03-65]).

There are at least two reasons to expect that the entire set of markers, including the 64 not previously identified, are likely to be useful signatures. The first, as indicated above, is that they are not only uniformly over or under-expressed, but the magnitude of the minimum differential expression is statistically significant, taking into account of the small sample size (see Section 3.3. for further analysis). Second, the set (158) and subset (64) are both highly enriched in cancer associated genes. In particular, of the 158 markers, 43 (27.2%) have been previously reported to be cancer associated as indicated in the Genetic association database or OMIM. In addition, 15 of the 64 are found to be cancer associated (23.4%). In comparison with the OMIM database, which includes 1351 cancer related genes (8.1%) out of 16603 total genes, 158 classifier genes are enriched 3.3 times (Fisher's exact test p-value = 1.6 × 10^−12^) with the cancer related genes; and 64 genes are enriched 2.9 times with p = 1. 6 × 10^−4^. Both results indicate that the enrichment of 158 genes and 64 genes with cancer genes is significant with respect to OMIM.

We also performed simulations by randomly selecting 158 genes from OMIM, and recorded the percentage of cancer associated genes. We tossed 1000 times, obtained a random distribution, and repeated the entire procedure 10 times to estimate the dispersion of the parameters of the 10 distributions. We obtained an average of 6.8% cancer related genes with a standard deviation 1.9 (The dispersion of both parameters is less than 2%). The actual percentage for 158 genes, 27.2%, is 10.7 standard deviations away from the random mean. We performed the same simulations by drawing randomly 64 genes, which yielded an average of 6.85% cancer related genes with a standard deviation 3.1. Hence, the actual percentage for 64 genes (23.2%) is 5.3 standard deviations away from the random mean. These results confirm that the percentage of cancer related marker genes are significantly different from what would be obtained randomly. Of the genes identified previously ([@b27-cin-03-65]) 220 (16%) are cancer associated; i.e. the 64 new genes are enriched nearly 50% more than the original set.

3.2.. Identifying biomarkers by SVM
-----------------------------------

The number of occurrences of the genes across the 18 top 20 rankings is given as [Supplementary Figure 1](#f6-cin-03-65){ref-type="supplementary-material"}. Each gene is shown by its rank (the highest ranked gene, i.e. gene \#1, occurs in the top 20, 17 out of 18 times; the number 2 ranked genes has 16 occurrences, the genes ranked 3 and 4 have 14 occurrences etc). Examination of the genes most frequently ranked in the top 20 reveals that they can all individually distinguish tumor from normal tissue with no error. More importantly, these are the genes that are most stable over different choices of training set (18 training sets each lacks one sample), suggesting that they would be the most likely to make accurate predictions in unseen tissue samples.

Genes ranked in the top 20 ([Table 2](#t2-cin-03-65){ref-type="table"}) were all identified as classifiers by the exhaustive search (Section 2.1), 17 with a p-value ≤0.01; i.e. 7/20 (85%) are in our set of 158 markers. Twelve of the genes were previously identified by Lenburg et al., two genes by four or more other RCC studies as well. HUGO (The Human Genome Organization) gene symbol (<http://www.gene.ucl.ac.uk/nomenclature/>) is used to represent the genes in [Table 2](#t2-cin-03-65){ref-type="table"} and throughout the paper.

Of the 20 genes, 7 had not been previously identified as RCC related, of those 5 are identified by both methods, and 2 of the five are implicated in other cancers.

3.3.. Small sample size
-----------------------

Although we confined ourselves to perfect separators with minimum separation distances that are highly significant, human polymorphism makes it unlikely that perfect separation will continue to hold as the population size increases. In an effort to gain some insight into this effect we analyzed a breast cancer data set ([@b30-cin-03-65]), which includes 32 normal samples and 53 breast cancer samples (30 ductal carcinoma *in situ* and 23 invasive ductal carcinoma samples). Raw data is available for 1940 genes which were found to be differentially expressed between normal and cancer stages by linear discriminant analysis ([@b30-cin-03-65]).

We drew random groups of 18 (9 normal, 9 tumor) and repeated the analysis of 2.1. The significant markers were then tested on the remaining samples. The entire procedure was repeated 100 times. Denoting tumor samples as positives and normal samples as negatives, the following performance measures were used for the classifier genes: *sensitivity* = TP/(TP+FN); *specificity* = TN/(TN+FP) and *positive predictive value (PPV)* = TP/(TP+FP) where TP stands for true positives, FP for false positives, TN for true negatives and FN for false negatives.

We first compared the performance of the classifier genes that have significantly high minimum distances (p-value ≤0.05) with all classifiers ([Table 3](#t3-cin-03-65){ref-type="table"}). The former group performs only slightly better (The simulations performed on different initial sample sizes confirmed this conclusion, data not shown) probably because the starting set (1940 genes) in breast cancer is pre-selected by discriminant analysis. The results suggest that the markers inferred using sample numbers comparable to RCC would still provide a very high degree of separation, even when more samples are used.

More direct testing was carried out by selecting different initial number of samples to compare the performance of the method with 18 samples, to other samples sizes, ranging from 8 (4 normal, 4 tumor) to 24 samples (12 normal, 12 tumor). In each case, we recorded the number of classifiers, number of significant classifiers (p-value ≤0.05) and the performance of the significant classifiers on the test samples (samples not selected initially to identify classifier genes). The number of significant genes were projected ([Supplementary Figure 2(a)](#f7-cin-03-65){ref-type="supplementary-material"}) based on the results of breast cancer simulations (inset). Overall, the number of classifiers and significant classifiers decreases as the number of samples increases. The performance of significant breast cancer markers (p ≤ 0.05) is shown in (b) and (c). Percentage of correctly classified samples increases with the sample size, having a plateau near 18 samples (b). The values for percentage of misclassified samples and unclassified samples obtained for 18 samples are very close to \>20 samples, but much better with respect to lower sample sizes. Sensitivity increases with the sample size, but specificity and PPV of the significant classifiers are independent of the number of samples. Hence, in all cases, the significant classifiers perform well on the test samples in terms of sensitivity and PPV irrespective of how many samples were used to select those classifiers. Overall, the performance of classifiers obtained with 18 samples is better than obtained with smaller number of samples (12, 14 or 16) and almost the same with larger number of samples (≥20 samples).

3.4.. RCC substructure
----------------------

We organized the markers into genetic networks using hierarchical clustering (HCL) and principal component analysis (PCA). HCL gives the distances between nodes (samples or genes) and reveals the substructure within nodes; PCA identifies the primary axes upon which the samples vary and how the samples are distributed along these axes based on the similarity between their expression profiles.

### 3.4.1.. HCL

Markers and samples were clustered by average-linkage hierarchical clustering ([Figure 3(a)](#f3-cin-03-65){ref-type="fig"}). Each marker is represented as a vector of normalized expression values across all samples and Euclidean distance between vectors was computed. An analogous procedure was used for samples. The distance between two clusters is defined as the distance between pairs of nodes, averaged over all pairs, each pair consisting of one node from each group. At each stage of clustering, the two clusters for which the distance is minimum, are merged. In the resulting dendrograms for samples (top) and genes (left), the height of vertical/horizontal lines are proportional to the degree of similarity between samples/genes.

The expression values are normalized for each gene by dividing every expression value to the mean of normal values for that gene and then transforming those values to logarithmic values (log~2~ transformation) to emphasize up or down-regulation with respect to normal expression values. The expression values are color coded such that red denotes up-regulation with respect to the mean of normal values, green denotes down-regulation and black denotes the mean of normal values. Two big clusters of genes are revealed: down-regulated genes in RCC (upper half) and up-regulated in RCC (bottom half) with respect to the normal samples, together with subclusters within these groups. We didn't examine these subclusters, but instead analyzed the expression profiles of groups of genes that are in the same pathway in Section 4.1. The markers cluster the samples well into two major groups ([Fig. 3a](#f3-cin-03-65){ref-type="fig"}, upper dendrogram). It is clear that tumor samples are separated into two major sub-clusters according to the grade. The only exception is T005 sample (grade I) which clusters with high grade samples for which we cannot provide a satisfactory biological explanation. Within the normal samples, N032 and N035 have expression profiles most similar to tumor samples. Clustering the data with PCA supports these observations as we now explain.

### 3.4.2.. PCA

PCA was applied to the 18 row × 158 column matrix of expression values, normalized as explained above. The eigenvectors of the first three eigenvalues accounted for 86.9% of the variation (81.5, 5.4 and 2.2, respectively) in the data. [Figure 3 (b)](#f3-cin-03-65){ref-type="fig"} shows the projection of the samples onto these first three principal components (PCs). The first PC separates normal samples from tumor samples while second PC separates tumor samples with low grade (T3, T023, T001, T2 and T4) from those of high grade (T011, T032, T035) with the exception of T005 sample, as observed with HCL. The third principal component separates normal samples N032 and N035 from the other normal samples. Two of the tumor samples, T3 and T2, are separated from other tumors along the second and third axes, respectively. Both samples are grade II tumors. As expected, PCA suggests that there is more variation within tumor samples than within normal samples, which points to distinct tumor subgroups, reflecting the heterogeneity in cancer phenotype and may have implications for disease progression and response to different therapies.

The separation of N032 and N035 from other normal samples was noted previously ([@b27-cin-03-65]) by clustering samples using all 20,192 genes. They observed that N035 clustered with tumor samples; however, we find that it clusters with normal samples as it should. The difference in results reflects our use of markers for clustering. The N032 and N035 profiles are more similar, than other normals, to tumor sample profiles ([Figure 3(a)](#f3-cin-03-65){ref-type="fig"}), but still they are more similar to normals than to tumor. Both samples are from RCC patients with grade III tumors, hence there is a possibility that these samples, which were classified as normal by standard histology, are actually a mixture of normal and cancerous tissue.

4.. Discussion
==============

4.1.. Pathway associations of markers
-------------------------------------

Biological roles of 158 markers ([Supplementary Table 1](#t7-cin-03-65){ref-type="table"}) were determined using DAVID ([@b8-cin-03-65]) and MatchMiner ([@b4-cin-03-65]) databases. 115 (73%) of the markers ([Table 4](#t4-cin-03-65){ref-type="table"}) are annotated in a KEGG pathway or a GO process at level 5 or higher. Genes that have been identified as having noteworthy differential gene expression in four or more RCC studies ([@b51-cin-03-65]; [@b3-cin-03-65]; [@b42-cin-03-65]; [@b9-cin-03-65]; [@b27-cin-03-65]) are indicated with \*\*. The 64 genes implicated in RCC in this study that were not reported by Lenburg et al. are indicated in italic.

Disease association was obtained from OMIM and the Genetic association databases. As summarized in [Table 4](#t4-cin-03-65){ref-type="table"}, 43 are cancer related. The relation between the cancer associated markers previously identified---as well as those identified by this study---and critical physiological changes associated with tumor development ([@b12-cin-03-65]) is also shown in [Table 4](#t4-cin-03-65){ref-type="table"} (third column, also see [Figure 5](#f5-cin-03-65){ref-type="fig"}). In particular column 3 includes (1) genes that were previously implicated in cancer e.g. tumor suppressors and oncogenes and (2) genes that were not previously found to be associated and whose role in transformative processes has not been established. As an example of the latter, we annotated proteolysis genes and genes involved in cell-adhesion and/or regulation of actin cytoskeleton as potentially involved in "tissue invasion and metastasis."

As summarized in [Table 4](#t4-cin-03-65){ref-type="table"}, the markers include several signaling proteins, some of them previously implicated in cancer transformation (Notch signaling, Wnt signaling, TGF-β signaling, NF-κB cascade and MAPK signaling cascades). The heatmap of signaling pathway genes is shown in [Figure 4(a)](#f4-cin-03-65){ref-type="fig"}. *Interestingly, all markers involved in calcium signaling pathways are down-regulated in RCC. Another interesting group of genes are immune system related genes, 83% of which are upregulated* ([Figure 4(b)](#f4-cin-03-65){ref-type="fig"}). Considering that RCC is resistant to chemo, radio and hormonal therapy while immunotherapy (cytokines IL-2 and interferon-alpha) appears to be effective for RCC treatment, these immune response related biomarkers could be potentially important for therapeutics. Our results also indicate that all cation and anion transport genes identified by our analysis---which encode mainly ion channels---are down-regulated ([Figure 4(c)](#f4-cin-03-65){ref-type="fig"}). Conversely, genes involved in intracellular transport and amino acid transport are mostly up-regulated. Since the kidney is at the junction of circulatory and urological processes both of which involve transport of different body fluids as well as ions; down-regulation of ion channels may be the result of a nonfunctioning kidney in RCC. Increase in intracellular transport point to increased communication of cancerous cells with ECM, with normal cells as well as with other cancer cells. Up-regulated amino acid transport shows that cancer cells need more building blocks to make proteins for different biological processes as they grow.

Other groups of genes potentially important for tumor progression include those for proteolysis, and cell-adhesion and/or regulation of actin cytoskeleton ([Figure 4(d)](#f4-cin-03-65){ref-type="fig"}). These genes are likely to be involved in tissue invasion and metastasis.

The apoptotic genes ([Figure 4(e)](#f4-cin-03-65){ref-type="fig"}) SPP1 and SFRP1 are candidate tumor suppressors for various cancers; AXL gene is a proto-oncogene, and NOL3 (ARC, apoptosis repressor with CARD domain) is induced in human breast cancer and confers chemo- and radiation-resistance ([@b32-cin-03-65]). These genes may all contribute to evasion of apoptosis during tumor development.

Finally, a number of markers are involved in metabolism; some are shown in [Figure 4(f)](#f4-cin-03-65){ref-type="fig"}. It is clear that the processes shown are all linked to energy generation in the cell and that most of these genes are suppressed in RCC. Studies by Warburg ([@b46-cin-03-65]) indicate that the vast majority of human and animal tumors display a high rate of glycolysis under aerobic conditions. Human solid tumors endure profound hypoxia; hence adaptation to hypoxic conditions is a crucial step in tumor progression. The anaerobic use of glucose as an energy source through glycolysis is therefore a feature common to solid tumors, in turn leading to a lesser dependence on the mitochondria for oxidative phosphorylation. This loss of cell dependence on oxidative metabolism is an important factor in the development of tumors. In accordance with that, it was shown that expression levels of OXPHOS genes were down-regulated in RCC ([@b40-cin-03-65]; [@b31-cin-03-65]). Hence, overall suppression of these genes can be due to loss of tumor dependence on normal energy generating pathways in hypoxic conditions.

4.2.. Disease associations
--------------------------

Eleven of the 158 biomarkers are especially definitive, both because of their biology, and because they have been identified as RCC related in four or more studies ([@b51-cin-03-65]; [@b3-cin-03-65]; [@b42-cin-03-65]; [@b9-cin-03-65]; [@b27-cin-03-65]). These genes are GABARAPL1, EGLN3, MT1G, SFRP1, INHBB, ATP6V1B1, APOC1, ADH6, C1QB, ALDOB and CNGLN. SFRP1 and EGLN3 are involved in apoptosis, which is a critical process as evasion of apoptosis is one of the key steps in tumorigenesis. CNGLN is involved in regulation of actin cytoskeleton, which may have a role in tissue invasion and metastasis. Four other genes have a role in metabolism, specifically glycolysis (ADH6, ALDOB), lipoprotein metabolism (APOC1), and oxidative phosphorylation (ATP6V1B1). INHBB and C1QB are immune response related genes. INHBB is a growth factor, hence its up-regulation may cause uncontrolled activation of downstream targets.

In addition to these eleven genes, 83 others were identified by Lenburg et al. as differentially expressed in RCC. They include carbonic anyhdrase IX, which is the RCC associated antigen G250 and is induced in many cancer types, hypoxia induced gene ADORA3, potentially oncogenic AXL gene which causes transformation when overexpressed in NIH 3T3 cells, and vitamin D receptor (VDR, up-regulated), which was found to be over-expressed in pancreatic cell lines ([@b1-cin-03-65]) and is down-regulated by resveratrol compound ([@b38-cin-03-65]) in RCC cell lines, which acts as a chemopreventive agent for RCC and other types of cancers.

Another 64 genes were not identified in our previous study. Of these genes 25 were found to be significantly up-/down-regulated (in the same direction with this study) by one or more other RCC studies as summarized in [Table 5](#t5-cin-03-65){ref-type="table"}. The overall summary of the 7 RCC studies and the overlap between their gene sets and our genes are given in [Supplementary Table 2](#t8-cin-03-65){ref-type="table"}.

TUBB, PRDX4 and ZNF395 genes are potentially important genes since they have been identified by four or more RCC studies including us. Some of the genes were already shown to be important in RCC by additional studies other than listed in [Table 5](#t5-cin-03-65){ref-type="table"}. These genes include SLC25A5 (ANT2, down), which catalyzes the exchange of ATP for ADP across the mitochondrial membrane, thus playing an important role in oxidative phosphorylation. Renal carcinomas were found to have reduced levels of ANT2 and other oxidative phosphorylation genes ([@b13-cin-03-65]) in line with the argument that the loss of cell dependence on oxidative metabolism is an important factor in the development of tumors under hypoxic conditions ([@b5-cin-03-65]). ALDOA enzyme (up), originally found to be up-regulated in lung cancer ([@b34-cin-03-65]), was determined to be an indicator of poor prognosis in RCC patients in combination with gamma-enolase ([@b44-cin-03-65]).

We further classified 64 markers into three groups ([Table 6](#t6-cin-03-65){ref-type="table"}) based on their disease associations: (I) previously reported RCC related genes ([Table 5](#t5-cin-03-65){ref-type="table"}), (II) genes related to cancers other than RCC, and (III) genes related to diseases other than cancer.

\(II\) These genes include NCOR2 (SMRT, up), which forms a large co-repressor complex that contains SIN3A/B and histone deacetylases HDAC1 and HDAC2. This complex associates with the thyroid (TR) and the retinoid acid receptors (RAR) in the absence of ligand, and may stabilize their interactions with TFIIB. Recently, it has been shown that elevated SMRT levels result in suppression of target genes for the vitamin D receptor (VDR) in prostate cancer cells and in apparent hormonal insensitivity ([@b25-cin-03-65]). ABL2 (up) tyrosine kinase is related to proto-oncogene ABL, and is implicated in hematologic neoplasms ([@b49-cin-03-65]) and gastric adenocarcinoma ([@b47-cin-03-65]).

CD81 antigen (up) is reported to influence adhesion, morphology, activation, proliferation, and differentiation of B, T, and other cells. Antibodies against CD81 induce homotypic aggregation of cells and can inhibit their growth. The loss of CD81 was found to be associated with differentiation and metastasis of HCC ([@b19-cin-03-65]). Betta-tubulin, TUBB, gene is implicated in many cancers including ovarian and lung cancer. Non-small cell lung cancers have a high incidence of somatic mutations of the beta-tubulin (class I) gene, which may cause paclitaxel resistance ([@b7-cin-03-65]). Moreover, recently, class III beta-tubulin overexpression was found to be a prominent mechanism of paclitaxel resistance in ovarian cancer patients ([@b33-cin-03-65]).

SART3 (squamous cell carcinoma antigen recognized by T cells 3), is an RNA-binding nuclear protein that is a tumor-rejection antigen. This antigen possesses tumor epitopes capable of inducing HLA-A24-restricted and tumor-specific cytotoxic T lymphocytes in colorectal cancer patients and may be useful for specific immunotherapy ([@b37-cin-03-65]). TFAP2 is known to suppress a number of genes including MCAM/MUC18, C/EBP alpha and MYC. The loss of this gene was shown to be to be associated with malignant transformation and tumor progression in malignant melanoma ([@b24-cin-03-65]; [@b21-cin-03-65]). This gene may be a potential tumor suppressor protein for RCC as well.

\(III\) Markers related to diseases other than cancer include WASF2, LCP2 and FYB (Wiscott-Aldrich syndrome, all up) and TAP2 (up, polymorphisms in this gene are implicated in type 1 diabetes ([@b28-cin-03-65]; [@b35-cin-03-65]). The relationship between Wiscott-Aldrich syndrome and diabetes should be elaborated in the future.

Other genes which we've identified as RCC related, but which have not previously been associated with any disease include ITPR2, which has roles in the calcium and phosphatidylinositol signaling pathways; glutaryl-Coenzyme A dehydrogenase (GCDH), which takes part in fatty acid metabolism,; 40S ribosomal protein S5 (RPS5), HIG1 (likely ortholog of hypoxia induced gene 1) and P4HB (proline 4-hydroxylase).

4.3.. Genes related to critical processes underlying kidney cell transformation
-------------------------------------------------------------------------------

The development of RCC, as with other cancers, is accompanied by alterations in cell physiology, which collectively dictate malignant growth ([@b12-cin-03-65]). Briefly these changes include environment independent growth; insensitivity to antigrowth factors (loss of tumor suppressor genes); evasion of apoptosis (producing survival factors); limitless replicative potential (turning on telomerase); sustained angiogenesis (producing VEGF inducer) and tissue invasion and metastasis (inactivation of E-cadherin). The order in which these capabilities are acquired is likely to be variable across different cancer types and subtypes. In this section we discuss RCC markers in the context of these alterations.

The main associations for RCC are summarized in ([Figure 5](#f5-cin-03-65){ref-type="fig"} and [Table 4](#t4-cin-03-65){ref-type="table"}). We include (1) genes that were previously implicated in cancer e.g. tumor suppressors and oncogenes and (2) genes that were not previously found to be associated with cancer but which have a function critical to tumor development. We did not include the genes whose expression is not correlated with the associated category e.g. NCOR2 gene ([Table 4](#t4-cin-03-65){ref-type="table"}) suppresses tumor growth in prostate cancer cells but is up-regulated in RCC, and hence it is not included. Our results suggest the following for RCC (1) Self-sufficiency in growth signals is achieved via activation of oncogenes JAZF1, AXL, ABL2; and growth factors INHBB and VGF. Further, loss of OXPHOS genes SLC25A5, ATP6V1B1, B3, V0A4, and NDUFA4 may contribute to the self-sufficiency of the cancer cells with the ability to be less dependent on OXPHOS (2) The loss of tumor suppressor genes PTPRO, TFAP2A, CDKN1C, AIM1 and MT1G as well as other genes that were shown to suppress tumor growth in cancer cell lines but not yet identified as tumor suppressor candidates (RASD1, VDR, EHF, SPP1, ACPP, MT1F and ERBB4) contributes to insensitivity to antigrowth signals; (3) Evasion of apoptosis is mediated through loss of SPP1 and SFRP1, and activation of TUBB, NOL3 and EGLN3. (4) Two groups of genes are likely to be involved in tissue invasion and metastasis: proteolysis genes (PAPPA, PSMB9 and MARCH-1) and genes involved in cell-adhesion and/or regulation of actin cytoskeleton (CNGLN, ITPR2, NPHS1, ITGB2, CLD1, ZAK, WASF2, CD81) and (5) Angiogenesis may be mediated through ALDOA enzyme which is shown to be activated by HIF1 under hypoxic conditions and by increased glycolytic activity (Warburg effect), and which in a feedback loop activates HIF1 ([@b29-cin-03-65]) which then activates several angiogenic factors including VEGF.

The identification of these genes opens up many paths for investigation that would not otherwise have been apparent. For example down regulation is often the result of epigenetic modification of upstream regions; especially methylation. The identification of CpG islands in or around binding sites and their analysis by RT-PCR or MALDI-TOF would be an obvious route to take, and if significant methylation difference are found, it would suggest a simple and sensitive assay for potentially significant markers.

Supplementary
=============

###### Number of occurrences of sorted genes in top 20 rankings. The highest ranked gene, ie gene \#1, has 17 occurrences across 18 top 20 lists.

###### Simulations on breast cancer dataset ([@b30-cin-03-65]) with different number of samples. **(a)** The number of significant genes projected for different number of samples based on the results of breast cancer simulations (inset). **(b)** and **(c)** Performance of significant breast cancer markers (p ≤ 0.05) on the test samples.

###### 

158 significant (p-value ≤0.01) markers.

  **GenBank Accession**   **Symbol**   **p-value**
  ----------------------- ------------ -------------
  NM_003221               TFAP2B       0
  NM_005235               ERBB4        0
  NM_017753               PRG-3        0
  NM_003714               STC2         1x10^−5^
  AI655467                             2x10^−5^
  BF478120                             2x10^−5^
  NM_001692               ATP6V1B1     2x10^−5^
  NM_002489               NDUFA4       2x10^−5^
  NM_012232               PTRF         2x10^−5^
  NM_021179               LOC57821     2x10^−5^
  NM_031412               GABARAPL1    2x10^−5^
  AI733359                             3x10^−5^
  NM_005950               MT1G         3x10^−5^
  NM_006990               WASF2        3x10^−5^
  NM_172369               C1QG         3x10^−5^
  BF541967                             5x10^−5^
  NM_002010               FGF9         5x10^−5^
  NM_033554               HLA-DPA1     5x10^−5^
  AI589190                             6x10^−5^
  BC005314.1                           6x10^−5^
  NM_004646               NPHS1        6x10^−5^
  NM_133262               ATP6V1G3     6x10^−5^
  NM_174896               MGC24133     6x10^−5^
  NM_002848               PTPRO        7x10^−5^
  NM_003113               SP100        7x10^−5^
  NM_014625               NPHS2        7x10^−5^
  NM_000339               SLC12A3      8x10^−5^
  NM_000491               C1QB         9x10^−5^
  NM_001009               RPS5         9x10^−5^
  NM_000767               CYP2B6       0.00011
  NM_003012               SFRP1        0.00011
  NM_004894               C14orf2      0.00011
  NM_016929               CLIC5        0.00011
  NM_022073               EGLN3        0.00011
  NM_033201               BC008967     0.00011
  NM_004356               CD81         0.00013
  NM_138799               OACT2        0.00013
  NM_000211               ITGB2        0.00014
  AK026764.1                           0.00015
  NM_152522               MGC33864     0.0003
  AV691491                             0.00033
  NM_004392               DACH1        0.00033
  NM_005565               LCP2         0.00033
  NM_014463               LSM3         0.00033
  NM_015474               SAMHD1       0.00036
  BG251556                             0.00037
  NM_018162               HELAD1       0.0004
  NM_000376               VDR          0.00043
  NM_001819               CHGB         0.00047
  NM_020142               NUOMS        0.00047
  NM_004578               RAB4A        0.00055
  AI962367                             0.00058
  NM_021800               DNAJC12      0.0006
  NM_021199               SQRDL        0.00061
  NM_153233               FLJ36445     0.00073
  NM_017606               NM_017606    0.0008
  NM_015488               MR-1         0.00084
  BF439449                             0.00093
  NM_000342               SLC4A1       0.00093
  NM_006120               HLA-DMA      0.00098
  NM_000918               P4HB         0.00108
  NM_001099               ACPP         0.00113
  NM_021151               CROT         0.00113
  BG434272                             0.00121
  NM_001216               CA9          0.00122
  NM_198991               KCTD1        0.00125
  NM_006312               NCOR2        0.00126
  NM_016582               SLC15A3      0.00142
  NM_020632               ATP6V0A4     0.00142
  NM_003220               TFAP2A       0.00166
  NM_005158               ABL2         0.00169
  NM_014601               EHD2         0.00169
  NM_003116               SPAG4        0.00185
  AW771565                AIM1         0.00187
  NM_003946               NOL3         0.00192
  NM_000076               CDKN1C       0.00195
  NM_006058               TNIP1        0.00197
  NM_000336               SCNN1B       0.00198
  NM_000035               ALDOB        0.00202
  NM_015103               PLXND1       0.00206
  BF130943                             0.00217
  BE552097                             0.00222
  NM_000672               ADH6         0.00248
  BE739519                             0.00259
  NM_198446               FLJ45459     0.00259
  NM_021958               HLX1         0.0026
  NM_001395               DUSP9        0.00262
  NM_018023               YEATS2       0.00267
  NM_001004196            CD200        0.00269
  NM_006520               TCTE1L       0.00275
  NM_001152               SLC25A5      0.00276
  NM_002193               INHBB        0.00277
  NM_006922               SCN3A        0.00277
  NM_000159               GCDH         0.0029
  NM_002800               PSMB9        0.00314
  NM_004051               BDH          0.00314
  NM_145040               PRKCDBP      0.0032
  N58278                               0.00325
  NM_024006               VKORC1       0.00335
  NM_004710               SYNGR2       0.00339
  AI796222                             0.00342
  NM_000161               GCH1         0.00348
  NM_000544               TAP2         0.00357
  NM_014706               SART3        0.00357
  NM_014056               HIG1         0.00362
  NM_001645               APOC1        0.00364
  NM_012153               EHF          0.00364
  NM_175061               JAZF1        0.00368
  NM_015991               C1QA         0.00379
  NM_145648               SLC15A4      0.00384
  NM_178014               TUBB         0.00391
  NM_000405               GM2A         0.00392
  AW242899                             0.00407
  NM_000582               SPP1         0.00408
  NM_002610               PDK1         0.00412
  NM_007021               C10orf10     0.00413
  NM_016084               RASD1        0.00423
  NM_016184               CLECSF6      0.00433
  NM_017923               MARCH-I      0.00438
  NM_015584               POLDIP2      0.00456
  NM_006406               PRDX4        0.00468
  NM_020991               CSH2         0.0047
  NM_000677               ADORA3       0.00478
  NM_002223               ITPR2        0.00483
  BF590528                             0.00485
  NM_005949               MT1F         0.00489
  NM_003038               SLC1A4       0.0049
  NM_001465               FYB          0.00503
  NM_004790               SLC22A6      0.00514
  NM_024027               COLEC11      0.00514
  AI769774                             0.00525
  NM_016653               ZAK          0.00525
  NM_014629               ARHGEF10     0.00527
  NM_000253               MTP          0.00571
  NM_003361               UMOD         0.00576
  BF510426                             0.00583
  NM_005531               IFI16        0.006
  AI282982                LOC120224    0.00629
  NM_004247               U5-116KD     0.00634
  NM_032118               FLJ12953     0.00641
  NM_004414               DSCR1        0.00655
  NM_032866               CNGLN        0.00665
  NM_002118               HLA-DMB      0.00719
  NM_004483               GCSH         0.00742
  NM_000316               PTHR1        0.00743
  T90295                               0.0076
  NM_030674               SLC38A1      0.00765
  NM_001699               AXL          0.00773
  AW242836                LOC120224    0.0078
  NM_205848               SYT6         0.00895
  NM_000034               ALDOA        0.00896
  NM_032717               MGC11324     0.00942
  NM_020139               DHRS6        0.00945
  AA148534                PAPPA        0.00951
  NM_016321               RHCG         0.00956
  H99792                               0.00983
  NM_053000               TIGA1        0.00983
  NM_018660               ZNF395       0.00994

###### 

Comparison with other RCC studies.

                     **Method**                                                                                                                                                      **number of samples/microarray platform**                           **Final number of genes**                    **Overlap with 158 marker genes**   **Overlap with 64[\*](#tfn6-cin-03-65){ref-type="table-fn"} marker-genes**
  ------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------- -------------------------------------------- ----------------------------------- ----------------------------------------------------------------------------
  [@b51-cin-03-65]   More than two-fold changed in two or more tumor samples                                                                                                         7 tumor (4 cc-RCC), 7 normal/cDNA 7,075 genes                       189                                          8                                   1
  [@b42-cin-03-65]   Three-fold or more changed in 75% or more of the tumor samples                                                                                                  29 cc-RCC and 29 normal/cDNA 21,632 genes                           109                                          7                                   \-
  [@b9-cin-03-65]    Changed genes in cc-RCC with Wilcoxon test p-value ≤0.001 and fold change ≥1.1                                                                                  13 RCC (9cc-RCC), 9 normal/ Affymetrix 5600 genes                   355 genes, 85 reported                       4                                   1
  [@b3-cin-03-65]    adapted sign test by counting for each gene the number of times that its measured intensity in the set of repeated pair-wise comparisons is higher in T and N   37 cc-RCC, 37 normal                                                1738 cDNAs                                   45                                  11
  [@b14-cin-03-65]   No reported gene set; selected genes with avg fold change \>3 and t-test p-value \>0.03.                                                                        41 RCC (23 cc-RCC), 3 normal/cDNA 22,648 genes                      182 genes                                    8                                   1
  [@b23-cin-03-65]   90% lower confidence boung of the fold change was \>2 and t-test p-value \<0.001                                                                                8 clear cell stage I, 23 normal, Affymetrix 22,283 genes            1359 up-regulated, 493 down-regulated        37 up, 19 down-regulated            15 up-regulated
  [@b41-cin-03-65]   t-test with estimated false discovery rate \<0.23                                                                                                               25 ccRCC, 25 normal/RCC-specific cDNA microarrays with 4207 genes   620 up-regulated; 561 down-regulated genes   13 up, 11 down-regulated            5 up, 2 down-regulated

genes not identified by Lenburg et al.

**Please note that this article may not be used for commercial purposes. For further information please refer to the copyright statement at <http://www.la-press.com/copyright.htm>**

![**(a)** The minimum distances of randomly formed expression profiles in four simulations are shown as representative of other simulations. The x-axis is the minimum distance and y-axis is the number of genes having that distance. **(b)** The distribution of minimum distances for 466 genes. 158 of these genes have minimum distances with p-values ≤0.01, hence identified as significant single gene biomarkers.](CIN-03-65-g001){#f1-cin-03-65}

![The relationship between minimum distance and average fold change (log2(C/N)). Average fold change was previously calculated by Lenburg et al. and the significance was found by t-test. Here, C and N denotes the average expression values in tumor and normal samples, respectively. Significant markers (p-value ≤0.01, 158 genes) are indicated as red. 64 genes are shown in between the vertical arrows. These genes have an average fold change less than 3 hence were not identified as previously differentially expressed. Yet, these genes have been identified as new potential biomarkers by the current algorithm.](CIN-03-65-g002){#f2-cin-03-65}

###### 

**(a)** Clustering of samples and 158 significant markers using hierarchical clustering. The expression values are normalized for each gene by dividing every expression value to the mean of normal values for that gene and then transforming those values to logarithmic values (log2) to emphasize up or down-regulation with respect to normal expression values. Black represents the mean of normal values, green represents down-regulation and red represents up-regulation with respect to the mean. Clustering of genes reveals two big clusters: down-regulated genes in RCC (upper half) and up-regulated in RCC (bottom half) with respect to the normal samples, together with subclusters within these groups. The markers cluster the samples perfectly well into two major groups ([Fig 3a](#f3-cin-03-65){ref-type="fig"}, upper dendrogram). It is clear that tumor samples are separated into two major sub-clusters according to the grade. The only exception is T005 sample (grade I) which clusters with high grade samples. Within the normal samples, N032 and N035 have expression profiles most similar to tumor samples. **(b)** The projection of the samples onto the first three principal components (PC). The eigenvectors of the first three eigenvalues accounted for 86.9% of the variation (81.5, 5.4 and 2.2, respectively) in the data. Tumor samples are represented by open circles; normal samples are shown by filled circles. First principle component separates normal samples from tumor samples while second principle component separates tumor samples with low grade (T3, T023, T001, T2 and T4) from high grade (T011, T032, T035) again with the exception of T005 sample. Third principal component separates normal samples N032 and N035 from the rest of the normal samples as was observed with HCL.
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###### 

Heatmaps of some of the important pathways that 158 markers are involved in. The expression values for each gene are transformed (Section 3.4.1) and color coded as in [Figure 3](#f3-cin-03-65){ref-type="fig"}. Black represents the mean of normal values, green represents down-regulation and red represents up-regulation with respect to the mean.
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![Genes related to critical processes underlying kidney cell transformation. Marker genes were replaced into six Weinberg categories which are essential for tumor development. Genes previously found by at least four other RCC studies are indicated with \*\*, genes implicated in other cancers with \*, and markers not identified previously by Lenburg et al. are given in red. Since the exact order of these steps is not known, the processes are given in here with no particular order.](CIN-03-65-g005){#f5-cin-03-65}

###### 

Top ranked pathways with percentage of significant classifier genes.

  **Pathway**                   **Number of classifier genes**   **Number of classifier genes/number of genes in the pathway (%)**
  ----------------------------- -------------------------------- -------------------------------------------------------------------
  Glycolysis                    5                                12.5
  Antigen processing            4                                11.76
  Oxidative phosphorylation     5                                3.36
  Calcium signaling pathway     4                                3.13
  G-Protein coupled signaling   4                                2.99
  MAPK signaling pathway        4                                2.06
  Immune response               14                               1.71
  Fatty acid metabolism         4                                1.53
  Cation transport              6                                1.19
  Apoptosis                     6                                0.98
  Intracellular transport       6                                0.95
  Regulation of transcription   12                               0.58
  Cell adhesion                 4                                0.56

###### 

Top 20 ranked genes by SVM and their significance as classifier by exhaustive search.

  **SVM rank**   **Gene**                                                                                       **p-value (min dist)**   **Min dist rank**   **Related disease**
  -------------- ---------------------------------------------------------------------------------------------- ------------------------ ------------------- --------------------------------------
  1              ALDOB[\*\*](#tfn2-cin-03-65){ref-type="table-fn"}                                              6.00E-05                 23                  RCC
  2              NDUFA4                                                                                         2.00E-05                 8                   
  3              TFAP2B[\*](#tfn3-cin-03-65){ref-type="table-fn"}                                               0                        1                   tumor suppressor candidate, melanoma
  4              TCTE1L                                                                                         0.00275                  93                  
  5              LOC57821                                                                                       2.00E-05                 11                  
  6              GABARAPL3[\*](#tfn3-cin-03-65){ref-type="table-fn"}[†](#tfn1-cin-03-65){ref-type="table-fn"}   0.02892                  239                 
  7              SLC38A1[\*](#tfn3-cin-03-65){ref-type="table-fn"}                                              7.00E-05                 27                  
  8              POLDIP2                                                                                        0.00456                  124                 
  9              DACH1                                                                                          0.00033                  43                  
  10             GABARAPL1[\*\*](#tfn2-cin-03-65){ref-type="table-fn"}                                          2.00E-05                 9                   RCC
  11             HLA-DPA1[\*](#tfn3-cin-03-65){ref-type="table-fn"}                                             5.00E-05                 16                  Melanoma
  12             ERBB4[\*](#tfn3-cin-03-65){ref-type="table-fn"}                                                0                        2                   Breast, ovarian cancer
  13             HIG1                                                                                           0.00362                  108                 hypoxia induced
  14             EHD2[\*](#tfn3-cin-03-65){ref-type="table-fn"}                                                 0.00169                  74                  
  15             CD81                                                                                           0.00013                  38                  Hepatoma
  16             PRG-3[\*](#tfn3-cin-03-65){ref-type="table-fn"}                                                0                        3                   
  17             NPHS1[\*](#tfn3-cin-03-65){ref-type="table-fn"}                                                6.00E-05                 19                  Non cancerous kidney diseases
  18             C1QA[\*](#tfn3-cin-03-65){ref-type="table-fn"}                                                 0.00379                  112                 
  19             ZNF697[†](#tfn1-cin-03-65){ref-type="table-fn"}                                                0.01543                  191                 
  20             PIGR[\*](#tfn3-cin-03-65){ref-type="table-fn"}[†](#tfn1-cin-03-65){ref-type="table-fn"}        0.38576                  432                 

^†^: minimum distance p-value \>0.01

identified by four or more RCC studies ([@b51-cin-03-65]; [@b3-cin-03-65]; [@b42-cin-03-65]; [@b9-cin-03-65]; [@b27-cin-03-65])

identified by Lenburg et al.

###### 

Performance of classifiers on the test samples in breast cancer dataset with 18 initial samples.

                                    **Classifiers with p-value ≤0.05**   **All classifiers**
  --------------------------------- ------------------------------------ ---------------------
  \% correctly classified samples   88%                                  82%
  \% misclassified samples          11%                                  18%
  Sensitivity                       0.87                                 0.8
  Specificity                       0.92                                 0.85
  PPV                               0.96                                 0.91

###### 

Biological roles (from KEGG and GO databases) and disease associations of 115 annotated gene markers.

  **Down-regulated genes**                                                                                                                                                                                                                                   
  ------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------- ---------------------------------------------------------------
  DUSP9                                                                                                                                                                                                                                                      MAPK Signaling/JNK cascade
  FGF9                                                    Prostate, ovarian cancer                                                                                                     Self-sufficiency in growth signals                                    MAPK Signaling/Regulation of actin cytoskeleton/growth factor
  *ITPR2*                                                                                                                                                                              Tissue invasion and metastasis                                        Calcium Signaling Pathway/Gap junction
  ERBB4                                                   Breast, ovarian cancer                                                                                                       Insensitivity to anti-growth signals                                  Calcium Signaling Pathway
  *SLC25A5*                                               RCC                                                                                                                          Self-sufficiency (Loss of cancer cell dependence on OXPHOS)           Calcium Signaling Pathway/Intracellular transport
  DSCR1                                                                                                                                                                                                                                                      Calcium Signaling Pathway
  PTHR1                                                   Chronic kidney failure                                                                                                                                                                             G-Protein coupled signaling
  RASD1                                                   Suppresses cell growth in human breast cancer and lung cancer cell lines                                                     Insensitivity to anti-growth signals                                  G-Protein coupled signaling
  SFRP1[\*\*](#tfn5-cin-03-65){ref-type="table-fn"}       RCC, bladder cancer, cervical cancer                                                                                         Evasion of apoptosis                                                  Wnt Signaling Pathway/Apoptosis
  *CHGB*                                                  Neuroendocrine tumors                                                                                                                                                                              Signaling/hormone
  PTPRO                                                   Lung cancer                                                                                                                  Insensitivity to anti-growth signals                                  Signaling/tumor suppressor candidate
  GABARAPL1[\*\*](#tfn5-cin-03-65){ref-type="table-fn"}   RCC                                                                                                                                                                                                Signaling
  ATP6V1G3                                                                                                                                                                             Self-sufficiency (Loss of cancer cell dependence on OXPHOS)           Oxidative phosphorylation
  ATP6V0A4                                                                                                                                                                             Self-sufficiency (Loss of cancer cell dependence on OXPHOS)           Oxidative phosphorylation
  ATP6V1B1[\*\*](#tfn5-cin-03-65){ref-type="table-fn"}    RCC/renal tubular acidosis                                                                                                   Self-sufficiency (Loss of cancer cell dependence on OXPHOS)           Oxidative phosphorylation
  KCTD1                                                                                                                                                                                                                                                      Cation transport
  SCNN1B                                                                                                                                                                                                                                                     Cation transport
  SLC12A3                                                                                                                                                                                                                                                    Cation transport
  SCN3A                                                                                                                                                                                                                                                      Cation transport
  EHO1                                                                                                                                                                                                                                                       Cation transport
  RHCG                                                                                                                                                                                                                                                       Cation transport
  SLC4A1                                                                                                                                                                                                                                                     Anion transport
  SLC12A3                                                                                                                                                                                                                                                    Anion transport
  SLC22A6                                                                                                                                                                                                                                                    Anion transport
  COLEC11                                                                                                                                                                                                                                                    Anion transport/Immune response
  CLIC5                                                                                                                                                                                                                                                      Anion transport
  MTP                                                                                                                                                                                                                                                        Intracellular transport
  *DACH1*                                                                                                                                                                                                                                                    Transcription regulation
  TFAP2B                                                  Char syndrome                                                                                                                                                                                      Transcription regulation
  *TFAP2A*                                                Melanoma                                                                                                                     Insensitivity to anti-growth signals                                  Transcription regulation/tumor suppressor candidate
  VDR                                                     RCC                                                                                                                          Insensitivity to anti-growth signals                                  Transcription regulation
  EHF                                                     Prostate, breast, and lung carcinomas                                                                                        Insensitivity to anti-growth signals                                  Transcriptional repressor
  *LSM3*                                                                                                                                                                                                                                                     RNA splicing
  RCQ5                                                                                                                                                                                                                                                       DNA repair
  *HELAD1*                                                Up in colorectal cancer                                                                                                      Limitless replicative potential                                       DNA replication
  PAPPA                                                                                                                                                                                Tissue invasion and metastasis                                        Proteolysis
  DNAJC12                                                                                                                                                                                                                                                    Protein folding
  CNGLN[\*\*](#tfn5-cin-03-65){ref-type="table-fn"}       RCC                                                                                                                          Tissue invasion and metastasis                                        Regulation of actin cytoskeleton
  AIM1                                                    Melanoma                                                                                                                     Insensitivity to anti-growth signals+Tissue invasion and metastases   Cell adhesion/ tumor suppressor candidate
  NPHS1                                                   Kidney diseases                                                                                                              Tissue invasion and metastasis                                        Cell adhesion
  *SPP1*                                                  down-regulated in RCC and intrahepatic cholangiocarcinoma; up-regulated in breast, prostate, colon (and others) carcinomas   Insensitivity to anti-growth signals                                  Cell adhesion/Apoptosis/Immune response
  CDKN1C                                                  Breast, pancreatic, thyroid cancer                                                                                           Insensitivity to anti-growth signals                                  Cell cycle/tumor suppressor gene
  UMOD                                                                                                                                                                                                                                                       Immune response
  ADH6[\*\*](#tfn5-cin-03-65){ref-type="table-fn"}        RCC                                                                                                                                                                                                Glycolysis/Fatty acid metabolism
  ALDOB[\*\*](#tfn5-cin-03-65){ref-type="table-fn"}       RCC, hepatocellular carcinoma                                                                                                                                                                      Glycolysis
  G3P2                                                                                                                                                                                                                                                       Glycolysis
  CYP2B6                                                  Breast cancer                                                                                                                                                                                      Fatty acid metabolism
  *GCDH*                                                                                                                                                                                                                                                     Fatty acid metabolism
  *CROT*                                                                                                                                                                                                                                                     Fatty acid metabolism
  MGC11324                                                                                                                                                                                                                                                   Membrane lipid metabolism
  BDH                                                                                                                                                                                                                                                        Synthesis and degradation of ketone bodies
  *NDUFA4*                                                                                                                                                                             Self-sufficiency (Loss of cancer cell dependence on OXPHOS)           Oxidative phosphorylation
  NPHS2                                                   Kidney diseases                                                                                                                                                                                    Energy metabolism
  GCSH                                                                                                                                                                                                                                                       Amino Acid metabolism
  GCH1                                                                                                                                                                                                                                                       Amino Acid metabolism
  ACPP                                                    Reduces cell growth in prostate cancer upon induction by Vitamin D receptor agonists                                         Insensitivity to anti-growth signals                                  Metabolism
  DHRS6                                                                                                                                                                                                                                                      Metabolism
  *HIG1*                                                                                                                                                                                                                                                     Hypoxia induced gene
  MT1G[\*\*](#tfn5-cin-03-65){ref-type="table-fn"}        RCC, papillary thyroid carcinoma, prostate cancer                                                                            Insensitivity to anti-growth signals                                  Metallothionein gene/tumor suppressor candidate
  MT1F                                                    Breast, liver cancer. Suppresses growth of liver cell line HepG2                                                             Insensitivity to anti-growth signals                                  Metallothionein gene

  **Up-regulated genes**                                                                                                                                                                                  
  --------------------------------------------------- ----------------------------------------------------------------------------- --------------------------------------------------------------------- ------------------------------------------------------------------------
  *CD81*                                              Hepatoma                                                                      Tissue invasion and metastasis                                        MAPK Signaling/Immune response/Membrane lipid metabolism/Cell adhesion
  *ZAK*                                                                                                                             Tissue invasion and metastasis                                        MAPK Signaling/Tight junction/Cell cycle
  ADORA3                                              ADORA3 agonists inhibit growth in leukemia and breast cancer cell lines       Insensitivity to anti-growth signals                                  G-Protein coupled signaling/Immune response/Hypoxia induced gene
  *WASF2*                                             Wiscott-Aldrich syndrome                                                      Tissue invasion and metastasis                                        G-Protein coupled signaling/Adherens junction
  *NCOR2*                                             Suppresses antiproliferative targets of VDR in prostate cancer                Insensitivity to anti-growth signals                                  Notch Signaling Pathway/transcriptional repressor
  CSH2                                                                                                                                                                                                    JAK-STAT Signaling Pathway
  *LCP2*                                              Wiscott-Aldrich syndrome                                                                                                                            Receptor protein Tyr-kinase Signaling
  INHBB[\*\*](#tfn5-cin-03-65){ref-type="table-fn"}   RCC                                                                           Self-sufficiency in growth signals                                    TGF-β Signaling Pathway /Immune response/growth factor
  STC2                                                Breast cancer                                                                                                                                       Signaling/hormone/renal and intestinal calcium and phosphate transport
  *PRDX4*                                                                                                                                                                                                 NF-κB cascade
  *PLXND1*                                                                                                                                                                                                Signaling
  C1QA                                                                                                                                                                                                    Immune response
  C1QG                                                                                                                                                                                                    Immune response
  C1QB[\*\*](#tfn5-cin-03-65){ref-type="table-fn"}    RCC                                                                                                                                                 Immune response
  SLC38A1                                                                                                                                                                                                 Amino Acid Transport
  *SLC1A4*                                                                                                                                                                                                Amino Acid Transport
  *TUBB*                                              Ovarian, lung cancer                                                          Evasion of apoptosis                                                  Intracellular transport/Apoptosis
  *TAP2*                                              Type 1 diabetes                                                                                                                                     Intracellular transport/Antigen processing
  *FYB*                                               Wiscott-Aldrich syndrome                                                                                                                            Intracellular transport
  *RAB4A*                                                                                                                                                                                                 Intracellular transport
  *YEATS2*                                                                                                                                                                                                Transcription regulation
  *PTRF*                                                                                                                                                                                                  Transcription regulation
  SP100                                               Liver diseases                                                                                                                                      Transcription regulation
  *JAZF1*                                             Endometrial stromal tumors                                                    Self-sufficiency in growth signals                                    Transcription regulation/oncogene
  IFI16                                               Head and neck squamous cell carcinomas. Up-regulation inhibits tumor growth   Insensitivity to anti-growth signals                                  Transcription regulation/ Antigen processing
  *HLX1*                                                                                                                                                                                                  Transcription regulation
  *ZNF395*                                                                                                                                                                                                Transcription regulation
  *RPS5*                                                                                                                                                                                                  Protein biosynthesis
  FUT11                                                                                                                                                                                                   Protein biosynthesis
  *U5-116KD*                                                                                                                                                                                              RNA splicing
  NOL3                                                Breast cancer                                                                 Evasion of apoptosis                                                  RNA splicing/anti-apoptotic
  *SART3*                                             Colorectal cancer                                                                                                                                   RNA processing
  PSMB9                                               RCC                                                                           Tissue invasion and metastasis                                        Proteolysis
  MARCH-I                                                                                                                           Tissue invasion and metastasis                                        Ubiquitin cycle
  ITGB2                                                                                                                             Tissue invasion and metastasis                                        Cell adhesion/Immune response
  *ABL2*                                              Gastric adenocarcinoma                                                        Self-sufficiency in growth signals + Tissue invasion and metastases   Focal adhesion/oncogene
  *CLD1*                                                                                                                            Tissue invasion and metastasis                                        Tight junction
  AXL                                                 RCC                                                                           Self-sufficiency in growth signals + Evasion of apoptosis             Apoptosis/oncogene
  EGLN3[\*\*](#tfn5-cin-03-65){ref-type="table-fn"}   RCC                                                                           Evasion of apoptosis                                                  Apoptosis
  CLECSF6                                                                                                                                                                                                 Immune response
  *TNIP1*                                                                                                                                                                                                 Immune response
  *HLA-DMA*                                                                                                                                                                                               Antigen processing
  HLA-DMB                                                                                                                                                                                                 Antigen processing
  HLA-DPA1                                            Melanoma                                                                                                                                            Antigen processing
  *SAMHD1*                                                                                                                                                                                                Interferon induction
  PDK1                                                                                                                                                                                                    Glycolysis/Gluconeogenesis
  *ALDOA*                                             RCC, HIF1 activated gene, also activates HIF1                                 Increased glycolysis (Warburg effect) + Angiogenesis                  Glycolysis/Gluconeogenesis
  GM2A                                                                                                                                                                                                    Membrane lipid metabolism
  *VKORC1*                                                                                                                                                                                                Biosynthesis of steroids
  NUOMS                                                                                                                                                                                                   Oxidative phosphorylation
  CA9                                                 RCC                                                                                                                                                 Nitrogen metabolism
  *SQRDL*                                                                                                                                                                                                 Energy metabolism
  APOC1[\*\*](#tfn5-cin-03-65){ref-type="table-fn"}   RCC                                                                                                                                                 Lipoprotein metabolism
  *P4HB*                                              May be HIF1 related                                                                                                                                 Metabolism
  VGF                                                                                                                               Self-sufficiency in growth signals                                    Growth factor

Genes in italic: 64 genes previously not reported by Lenburg et al.

genes previously reported by 4 or more RCC studies

###### 

25 genes that were not identified by Lenburg et al but identified by other RCC studies including this study.

![](CIN-03-65-t005)

###### 

Disease related 64 markers not identified by Lenburg et al.

  **Genes related to cancers other than RCC**          
  --------------------------------------------- ------ ------------------------------------------------------------------------------------------------------------------------------------------
  NCOR2                                         Up     Suppresses target genes for the vitamin D receptor (VDR) in prostate cancer cells resulting in hormonal insensitivity ([@b25-cin-03-65])
  ABL2                                          Up     Related to proto-oncogene ABL. Implicated in hematologic neoplasms ([@b49-cin-03-65]) and gastric adenocarcinoma ([@b47-cin-03-65])
  CD81                                          Up     The loss of CD81 was found to be associated with differentiation and metastasis of HCC ([@b19-cin-03-65])
  TUBB                                          Up     Implicated in many cancers including ovarian ([@b33-cin-03-65]) and lung cancer ([@b7-cin-03-65])
  SART3                                         Up     Induces HLA-A24-restricted and tumor-specific cytotoxic T lymphocytes in colorectal cancer patients ([@b37-cin-03-65])
  HELAD1                                        Down   Up-regulated in colorectal carcinomas ([@b20-cin-03-65])
  CHGB                                          Down   Up-regulated in neuroendocrine tumors ([@b26-cin-03-65])
  JAZF1                                         Up     Frequent fusion of the JAZF1 and JJAZ1 genes in endometrial stromal tumors ([@b18-cin-03-65])
  PRKCDBP                                       Up     epigenetic or mutational inactivation contribute to the pathogenesis of breast and lung cancers ([@b48-cin-03-65])
  TFAP2A                                        Down   Loss of AP-2 results in metastasis of melanoma cells ([@b21-cin-03-65])

  **Genes related to diseases other than cancer**        
  ------------------------------------------------- ---- --------------------------
  WASF2                                             Up   Wiscott-Aldrich syndrome
  LCP2                                              Up   Wiscott-Aldrich syndrome
  FYB                                               Up   Wiscott-Aldrich syndrome
  TAP2                                              Up   Type 1 diabetes
